Interestingly, compared to RAWTNF−α − CM group, the viability of BPH-1 cells decreased by approximately 25% when treated with RAWTNF−α +ITLN−1 − CM (P = 0.0002; Fig. 3B). The gene discussed is ITLN1; the disease is benign prostatic hyperplasia.